Athira Pharma's explosive growth potential is attributed to its innovative therapies aimed at neurological disorders, such as Alzheimer’s, Parkinson’s disease dementia, and dementia with Lewy bodies. The flagship molecule, ATH-107 (also known as fosgonimeton or fosgo), currently in advanced clinical testing, targets the HGF/MET system to promote neuronal health...
Athira, which made a good rally after the positive news from the company, may form the shoulder head shoulder pattern after first filling its gap around $2.45. Then, after breaking this shoulder head shoulder pattern, it can fill its big gap at $8.
Im a beginner so this should be pretty easy to understand.
This is simply a decent company having some internal issues, but those issues have seemingly been taken care of. The stock now seems to be starting its move back upward. Resistance has been broken, as well as what looks like a strong upwards trend is beginning. A few upcoming catalysts in the next few...
Fundamentals: ATHA is a biotech company whose primary product is focuses on Alzheimer's disease. This is product, if approved, promises to be in a very high demand. Recently company issued additional shares, which send the stock plummeting.
Technicals: ATHA might be working out on a 2nd wave. If this hypothesis proves true, the next 3rd wave can get the stock to...
Offering was for 4 million shares at 22.50 per share , expected to close on Jan 25th .
I took a position in the aftermarket today after finding this .
I like it for the following reasons:
-We are trading under book , P/B is 0.59
-Institution ownership is 67.30% I think this will help to reduce further sell off at these prices .
-Trading closed below the...
